AstraZeneca to Expand Montgomery County Manufacturing Operations
Global biopharmaceutical firm AstraZeneca is investing $300 million in an 84,000-square-foot manufacturing facility in Rockville, MD to launch its cell therapy platforms in the U.S. for critical cancer trials and future commercial supply. Located at 9950 Medical Center Dr., it is expected to become operational in 2026.
More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas.
The Rockville facility is located less than five miles from one of the company’s five global R&D centers and sits within the life sciences corridor in Maryland. The company recently signed a full-building lease in Gaithersburg.
Maryland Gov. Wes Moore said: “AstraZeneca and the State of Maryland share a deep commitment to innovation. It makes us the perfect pairing for this next-generation cell therapy facility. This significant investment in our life sciences sector will help maintain Maryland’s leadership in the industry and sharpen our competitive edge.”
Paul Bubny serves as Senior Content Director for Connect Commercial Real Estate, a role to which he brings 16-plus years’ experience covering the commercial real estate industry and 30-plus years in business-to-business journalism. In this capacity, he oversees daily operations while also reporting on both local/regional markets and national trends, covering individual transactions across all property types, as well as delving into broader subject matter. He produces 7-10 daily news stories per day and works with the Connect team and clients to develop longer-form content, ranging from Q&As to thought-leadership pieces.
Prior to joining Connect, Paul was Managing Editor for both Real Estate Forum and GlobeSt.com at American Lawyer Media, where he oversaw operations at both publications while also producing daily news and feature-length articles. His tenure in B2B publishing stretches back into the print era, and he has served as Editor in Chief on four national trade publications.
Since 1999, Paul has volunteered as the newsletter editor of passenger rail advocacy groups (one national, one local).